Boston Scientific Shares Drop Amid Cybersecurity Incident and Product Recall
On August 26, Boston Scientific (NYSE:BSX) shares fell nearly 5% following a cybersecurity incident that disrupted global operations and shipping. The company also announced the recall of certain percutaneous catheters tied to its ENROUTE Transcarotid Neuroprotection System due to FDA concerns about potential product failure. The stock closed at $48.17, with trading volume reaching 31.8 million shares—significantly higher than its three-month average. The broader market saw modest declines as the S&P 500 fell 0.04% and the Nasdaq Composite dropped 0.08%. Medical device peers like Abbott Laboratories (NYSE:ABT) also declined, while Medtronic (NYSE:MDT) rose slightly. Boston Scientific's stock has already fallen over 55% in a year amid ongoing challenges including weak earnings results, disappointing product sales, and financial pressures from an acquisition. Management is working to restore systems but cannot yet assess the full impact of these events on its shares.
Topics: cybersecurity medical devices product recall stock market